home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

FDA Quarterly Update–June, 2010

 
  May 12, 2010  
     
 
CfPA - The Center for Professional Advancement, 90 Minute Accredited Online Training
June 1, 2010 at 11:00 a.m.–12:30 p.m. (ET)


Who Should Attend
This course is designed for professionals in the pharmaceutical, device and biologics industries. It will be especially beneficial to:

  • Regulatory/QA Managers 
  • Directors and VPs 
  • Planning Executives anticipating FDA changes

Description
Our June, 2010 FDA Update Report is a careful distillation identifying the three most important new initiatives, regulatory changes and innovations from the FDA, and places them in context for the pharmaceutical, biological and device professional. This 90-minute accredited online training is divided into three sections, each section devoted to a new FDA regulation or initiative. The topics for June, 2010 are:

Module 1: New device classification and predicate policy:
  • Additional clinical study requirements for safety and 
    efficacy
  • Limiting the use of predicates and grandfathered devices
  • Increased requirements for PMA data

Module 2: H1N1 plans:
  • Epidemiological expectations
  • The annual flu vaccine
  • Strategy for distribution and acceptance

Module 3: Safe use initiative (drugs):
  • The Initiative explained
  • Implications for new drug approvals
  • Shift of FDA emphasis

Question and Answer Session

 
 
Organized by: CfPA - The Center for Professional Advancement
Invited Speakers: Dr. Sandy Weinberg, Associate Professor of Health Care Management (Regulation) at Clayton State University, part of the Georgia State University System; retired regulatory professional from the drug, device and vaccine industries

Dr. Weinberg is teaching and researching Regulation and Biodefense. He is a consultant to the FDA regulated industries and is a former consultant to the FDA and other international regulatory agencies including Health Canada, NIH, CDC, EMEA and the Swiss Ministry of Health.

He has been a leader in the field of system validation for more than twenty years, and a practitioner in regulatory submissions, auditing, international liaison and biodefense vaccine development. Dr. Weinberg is the author of numerous books and articles, including The GALP Regulatory Handbook, The Handbook of System Validation, Good Laboratory Practice Regulations, and The Handbook of Drug Regulatory Submissions. His most recent articles include “Cost Effective Validation for LIMS” and “Conforming to Part 11 Regulations”.

Dr. Weinberg is a member of the Board of the KEMA Registered Quality (ISO 9000 Certifier) in the United States and the Netherlands. Recently retired, Dr. Weinberg was Senior Director for Biodefense at GE Healthcare and Vice President of Tikvah Therapeutics; as well as an investor in and Board member of several international biomedical companies.

Working as a consultant, Dr. Weinberg provides auditing and advisory services in regulatory areas. Recent projects include the auditing and certification of a chromatography control system; a business development and fund raising project for a biodefense vaccine company; an Orphan Drug submission; and the validation of a Laboratory Information Management System. Much of Dr. Weinberg’s practice is centered in the US, Western Europe and Israel.
 
Deadline for Abstracts: n/a
 
Registration: Please click here for registration information.
E-mail: sberg@cfpa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.